Affibody’s Partner ACELYRIN Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
Prenumeration
• The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis.
• HiSCR75 did meet statistical significance at week 16 in a Last Observation Carried Forward sensitivity analysis.
• HiSCR response rates of izokibep 160mg weekly (QW) were consistent with Part A open label results, demonstrating early onset of HiSCR100 at week 4, increasing through week 12 to 38% of patients in the Independently Conducted Pre-Planned Interim Analysis.
• Response was dose ordered, and safety was consistent with prior izokibep experience and not dose-limiting.
• Izokibep appears to be demonstrating consistent early and high orders of response without safety or tolerability limitation.
Solna, Sweden, September 11, 2023. Affibody’s partner ACELYRIN, INC. today announced top-line results from Part B of a Phase 2b/3 trial evaluating izokibep for the treatment of moderate-to-severe Hidradenitis Suppurativa (HS). The primary endpoint of HiSCR75 at week 16 did not meet statistical significance. However, response rates for izokibep showed early HiSCR100 responses, a clear dose-effect supported by both pharmacokinetic exposures and HiSCR responses favoring 160mg weekly dosing, and no evidence of safety or tolerability limitation.
“Although the overall study did not meet statistical significance, as reported by our partner ACELYRIN, izokibep appears to be demonstrating high orders of response for patients suffering from hidradenitis suppurativa without safety or tolerability limitations,” said David Bejker, CEO of Affibody. “The consistent and early achievement of HiSCR100, along with the prior izokibep experience in Psoriatic Arthritis (PsA), continues to demonstrate the potential of izokibep for resolution of disease, especially in difficult to treat tissues. Our partner continues to evaluate izokibep in additional ongoing late-stage trials in HS, PsA, and uveitis, with top-line data for the Phase 2b/3 trial in PsA expected in Q1, 2024.”
The randomized double-blind, placebo-controlled, multi-center trial evaluated the safety and efficacy of izokibep dosed 160 mg weekly (QW) and every two weeks (Q2W), versus placebo, in 175 patients with moderate-to-severe HS (Hurley Stage II and III). The trial was conducted at 50 sites globally and assessed various efficacy endpoints, including the primary endpoint of HiSCR75 (Hidradenitis Suppurativa Clinical Response) at 16 weeks utilizing a non-responder imputation (NRI) analysis method.
In the primary NRI analysis of Part B, statistical significance was impacted by patients with HiSCR75-100 discontinuing as early as week 4 unrelated to adverse events. In addition, there was a marked increase in placebo rates during the course of the study. Applying a Last Observation Carried Forward (LOCF) sensitivity analysis of the full dataset highlighted the impact of responder discontinuations on the primary analysis and showed statistical significance of HiSCR75 at week 16.
| Endpoint | Part B NRI Izokibep 160 mg QW (n=57) | Part B NRI Izokibep 160 mg Q2W (n=59) | Part B NRI Placebo (n=59) |
| HiSCR75 p-value | 39% 0.3278 | 34% 0.5997 | 29% |
| HiSCR100 p-value | 26% 0.0595 | 22% 0.1408 | 12% |
| Endpoint | Part B LOCF Izokibep 160 mg QW (n=54) | Part B LOCF Izokibep 160 mg Q2W (n=57) | Part B LOCF Placebo (n=57) |
| HiSCR75 p-value | 51% 0.0423 | 36% 0.7451 | 32% |
| HiSCR100 p-value | 30% 0.0751 | 22% 0.3558 | 15% |
An independently conducted pre-planned interim analysis, to which the company remained blinded until the time of this primary analysis, occurred prior to a rise in placebo rates observed later in the trial. This dataset provides an opportunity to view the performance of izokibep prior to this increase. The table below shows the consistency of Part A open label results relative to the Part B placebo-controlled interim analysis, which was pre-specified to be an as observed analysis at week 12.
| Endpoint | Part A Izokibep 160 mg QW (n=21) | Part B Interim Izokibep 160 mg QW (n=21) | Part B Interim Izokibep 160 mg Q2W (n=27) | Part B Interim Placebo (n=23) |
| HiSCR75 p-value | 57% | 52% 0.018 | 30% 0.435 | 17% |
| HiSCR100 p-value | 33% | 38% 0.009 | 11% 0.518 | 4% |
Also, given the number of responders who discontinued in the QW arm – the majority unrelated to an adverse event – a modified-NRI (mNRI) approach showed a high level of statistical significance and highlighted the impact of discontinuations on magnitude and significance of response. This analysis demonstrates the performance of izokibep at this juncture in the study – in isolation from the placebo rate increases observed later in the trial – and provides an exploratory approach to analyzing responder discontinuations.
| Endpoint | Part B Interim mNRI Izokibep 160 mg QW (n=31) | Part B Interim mNRI Izokibep 160 mg Q2W (n=28) | Part B Interim mNRI Placebo (n=27) |
| HiSCR75 p-value | 45% 0.0062 | 25% | 15% |
| HiSCR100 p-value | 29% 0.0054 | 11% | 4% |
The safety profile for izokibep was consistent with prior studies and the anti-IL-17A class. There were no events of candida in the high dose 160mg QW arm and there were two discontinuations across the trial due to injection site reactions (3.5%).